Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ACVR1B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ACVR1B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ACVR1B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ACVR1B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0034101 | Colorectum | AD | erythrocyte homeostasis | 51/3918 | 129/18723 | 1.07e-06 | 3.59e-05 | 51 |
GO:0030099 | Colorectum | AD | myeloid cell differentiation | 119/3918 | 381/18723 | 1.24e-06 | 4.01e-05 | 119 |
GO:0016049 | Colorectum | AD | cell growth | 143/3918 | 482/18723 | 2.83e-06 | 8.09e-05 | 143 |
GO:0002262 | Colorectum | AD | myeloid cell homeostasis | 57/3918 | 157/18723 | 6.17e-06 | 1.56e-04 | 57 |
GO:0001558 | Colorectum | AD | regulation of cell growth | 124/3918 | 414/18723 | 7.67e-06 | 1.86e-04 | 124 |
GO:0048872 | Colorectum | AD | homeostasis of number of cells | 87/3918 | 272/18723 | 1.16e-05 | 2.61e-04 | 87 |
GO:0001667 | Colorectum | AD | ameboidal-type cell migration | 137/3918 | 475/18723 | 2.17e-05 | 4.33e-04 | 137 |
GO:0030218 | Colorectum | AD | erythrocyte differentiation | 45/3918 | 120/18723 | 2.22e-05 | 4.39e-04 | 45 |
GO:0001701 | Colorectum | AD | in utero embryonic development | 110/3918 | 367/18723 | 2.36e-05 | 4.62e-04 | 110 |
GO:0046777 | Colorectum | AD | protein autophosphorylation | 74/3918 | 227/18723 | 2.48e-05 | 4.76e-04 | 74 |
GO:0097191 | Colorectum | AD | extrinsic apoptotic signaling pathway | 68/3918 | 219/18723 | 2.64e-04 | 3.27e-03 | 68 |
GO:0045646 | Colorectum | AD | regulation of erythrocyte differentiation | 20/3918 | 47/18723 | 6.54e-04 | 6.75e-03 | 20 |
GO:0007178 | Colorectum | AD | transmembrane receptor protein serine/threonine kinase signaling pathway | 99/3918 | 355/18723 | 9.92e-04 | 9.28e-03 | 99 |
GO:0018210 | Colorectum | AD | peptidyl-threonine modification | 40/3918 | 125/18723 | 2.44e-03 | 1.88e-02 | 40 |
GO:1903706 | Colorectum | AD | regulation of hemopoiesis | 99/3918 | 367/18723 | 3.08e-03 | 2.28e-02 | 99 |
GO:0045637 | Colorectum | AD | regulation of myeloid cell differentiation | 61/3918 | 210/18723 | 3.17e-03 | 2.35e-02 | 61 |
GO:0018107 | Colorectum | AD | peptidyl-threonine phosphorylation | 37/3918 | 116/18723 | 3.68e-03 | 2.61e-02 | 37 |
GO:0045926 | Colorectum | AD | negative regulation of growth | 70/3918 | 249/18723 | 4.07e-03 | 2.83e-02 | 70 |
GO:0008544 | Colorectum | AD | epidermis development | 87/3918 | 324/18723 | 5.99e-03 | 3.76e-02 | 87 |
GO:00160493 | Colorectum | FAP | cell growth | 112/2622 | 482/18723 | 2.40e-08 | 2.30e-06 | 112 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ACVR1B | SNV | Missense_Mutation | novel | c.724N>T | p.Arg242Trp | p.R242W | P36896 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
ACVR1B | SNV | Missense_Mutation | novel | c.1193C>T | p.Ala398Val | p.A398V | P36896 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ACVR1B | SNV | Missense_Mutation | rs776103829 | c.1055N>T | p.Ala352Val | p.A352V | P36896 | protein_coding | tolerated(0.69) | benign(0.083) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ACVR1B | SNV | Missense_Mutation | rs769120851 | c.1090G>A | p.Val364Met | p.V364M | P36896 | protein_coding | tolerated(0.07) | benign(0.216) | TCGA-BS-A0UA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ACVR1B | SNV | Missense_Mutation | | c.1574G>T | p.Arg525Leu | p.R525L | P36896 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BS-A0UA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ACVR1B | SNV | Missense_Mutation | | c.385N>T | p.Gly129Cys | p.G129C | P36896 | protein_coding | tolerated(0.06) | possibly_damaging(0.605) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ACVR1B | SNV | Missense_Mutation | rs576155472 | c.104C>T | p.Ala35Val | p.A35V | P36896 | protein_coding | tolerated(0.55) | benign(0) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
ACVR1B | SNV | Missense_Mutation | rs748742473 | c.143N>T | p.Thr48Ile | p.T48I | P36896 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
ACVR1B | SNV | Missense_Mutation | rs751308109 | c.271N>T | p.Arg91Cys | p.R91C | P36896 | protein_coding | tolerated(0.09) | possibly_damaging(0.781) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
ACVR1B | SNV | Missense_Mutation | | c.985G>A | p.Gly329Arg | p.G329R | P36896 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E6-A2P8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
91 | ACVR1B | SERINE THREONINE KINASE, CELL SURFACE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | 249565824 | | |
91 | ACVR1B | SERINE THREONINE KINASE, CELL SURFACE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | 249565787 | VACTOSERTIB | |
91 | ACVR1B | SERINE THREONINE KINASE, CELL SURFACE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | 223366128 | GALUNISERTIB | |
91 | ACVR1B | SERINE THREONINE KINASE, CELL SURFACE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | US10030004, Compound 11a | | |
91 | ACVR1B | SERINE THREONINE KINASE, CELL SURFACE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | 404859109 | | |
91 | ACVR1B | SERINE THREONINE KINASE, CELL SURFACE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | US10030004, Compound 19 | | |
91 | ACVR1B | SERINE THREONINE KINASE, CELL SURFACE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | BDBM108945 | | |
91 | ACVR1B | SERINE THREONINE KINASE, CELL SURFACE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | US9682983, 1 | | |
91 | ACVR1B | SERINE THREONINE KINASE, CELL SURFACE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | US10030004, Compound 33 | | |
91 | ACVR1B | SERINE THREONINE KINASE, CELL SURFACE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | 249565800 | | |